Search

Hepatic ischemia-reperfusion injury (IRI) is a pathophysiological and huge challenge during liver surgical procedures. Herein, virus-mimicking liposomal system based on dendritic lipopeptides for efficient prevention of IRI is reported. These virus-mimicking liposomes not only have virus-like nanostructures and components, but also possess virus-like infections to liver tissue, liver cells, and organelles. The distinguished features for prevention of IRI of viral mimics are as follows: (i) viral envelope-like structure to help avoid the host immune system; (ii) well-defined nanostructure and surface to improve the accumulated efficiency in liver tissue; (iii) viral capsids mimic to enhance liver cell uptake and achieve mitochondrial targeting. This type of virus-mimicking design makes prevention of IRI by drug-loading greatly exceed the control groups with high biocompatibility and facile manufacturing.

Hypertrophic scar is a complex global disease, which can lead to remarkable functional impairment, pruritus, and pain. Treating local skin diseases needs a transdermal drug delivery system that can simultaneously promote cell and tissue penetration within the hypertrophic scar. Herein, a tissue and cell dual‐penetrating liposomal delivery platform consisting of arginine‐based dendritic lipopeptide mimicking the pivotal amino acid sequence in viral protein transduction domains and virion‐like nanostructure to enhance hypertrophic scar tissue deep penetration and cellular internalization is reported. This dendritic lipopeptide liposomal delivery platform can overcome corneum barriers to the punch on hypertrophic scar fibroblast membranes, as are natural viruses. It also can deeply deliver drugs to promote hypertrophic scar fibroblast apoptosis and collagen fiber remodeling within thickened dermis and epidermis, and finally remove the raised scars. [ABSTRACT FROM AUTHOR]